TOKYO, Aug 22, 2024 – (JCN Newswire via SeaPRwire.com) – Mitsubishi Heavy Industries, Ltd. (MHI), together with Kirin Group companies Kirin Beverage Co., Ltd. and Kirin Group Logistics Co., Ltd., in August will begin a joint demonstration aimed at establishing elemental technologies for the automation of inbound and outbound processes at beverage warehouses, and the […]
Category: JCN Newswire
Techstars Tokyo Accelerator Announces Inaugural Class of 2024
TOKYO, Aug 22, 2024 – (JCN Newswire via SeaPRwire.com) – Techstars Tokyo Accelerator powered by JETRO and Mitsui Fudosan is proud to announce the 12 startups selected for the Class of 2024. These promising, early-stage companies are addressing challenges in categories such as Women’s Health, Gaming, Animation, Productivity Enhancement, B2B Business Intelligence, Robotics and more. […]
Mitsubishi Ralliart’s Triton Finishes in Fifth Place Overall in Asia Cross Country Rally 2024: Team Determined to Make a Comeback Next Year
TOKYO, Aug 21, 2024 – (JCN Newswire via SeaPRwire.com) – Mitsubishi Motors Corporation (hereafter, Mitsubishi Motors) announced that Team Mitsubishi…
Valuufy Established to Transform Sustainable Business and Investing
KYOTO, JAPAN, Aug 14, 2024 – (JCN Newswire via SeaPRwire.com) – Valuufy, a pioneering fintech startup drawn from a decades’ work in measuring and creating sustainable value at Doshisha University’s Value Research Center, has launched with its groundbreaking ValuuCompass, a comprehensive framework set to transform sustainable business practices and sustainability investing by providing a fully […]
“LEQEMBI” (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in the United Arab Emirates
TOKYO and CAMBRIDGE, Mass., Aug 14, 2024 – (JCN Newswire via SeaPRwire.com) – Eisai Co., Ltd. and Biogen Inc. announced today that the Ministry of Health and Prevention in the United Arab Emirates (UAE) has approved humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody “LEQEMBI®” (lecanemab) for the treatment of Alzheimer’s disease (AD). Treatment with LEQEMBI […]


